Lilalutide and Lilalutide injections in Tonghua Dongbao have been approved by the State Drug Administration

October 11, Tonghua Dongbao Pharmaceuticals LimitedCompany("Tonghua Dongbao") announcement shows that the company declared liraglutide (receiving number CXSL1700142), liraglutide injection (receiving number CXSL1700143)drug(clinical) recently receive
d approval from the State Drug Administrationdrug (clinical testing
)on liraglutideliraglutide is a human pancreas-high-glycosin-like peptide-1 (GLP-1) analoguce used to treat diabetesGLP-1 has a variety of physiological functions: blood glucose dependence to promote insulin secretion, protect islet beta cells, delay stomach drainage to reduce appetite, etc, is the rise of diabetes treatment in recent yearsThe natural GLP-1 half-life is too short to be medicinal, so extending the half-life has become the main technological innovation point in the development of GLP-1 receptor agonist drugsin recent years, GLP-1 receptor agonists have grown fastest in the sugar-reducing drug market, becoming the biggest driver of expansion in the diabetes marketdrug-related situation
drug name: Lilalutidedosage form:API(spec: nobatch number: 2018L03096Application: domestic drug registrationApplicant: Tonghua Dongbao Pharmaceutical Co., Ltdacceptance number: CXSL1700142 ji
registration classification: therapeutic biological products
drug name: Lalupin injectiondosage form: injectionspecifications: 3 ml: 18mg (pre-filled injection pen)lot number: 2018L03097Application: Therapeutic BiologicsApplicants: Tonghua Dongbao Pharmaceutical Co., LtdAcceptance Number: CXSL1700143Registration Classification: Therapeutic Biological products